News

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory processes .

Cerillo and Opentrons are automating microbiome research and the discovery of microbiome therapeutics by seamlessly integrating Cerillo’s miniaturized Alto™ and Stratus® microplate readers onto the OT-2 and Flex for deck ELISA and cell growth analysis. This integration enables easy setup of experiments, including bacterial co­culture studies with Cerillo’s Co-culture platform.

According to Eric Mayton, CEO of Cerillo, “The integration of Cerillo’s products with Opentrons’ platforms aligns with our mission to provide accessible, cost effective, user-friendly laboratory tools that efficiently standardize global microbiome research at the bench. Our alignment with Opentrons’ open-source robotics platform sets new standards for industry efficiency.”

Cerillo’s Microbiome Discovery Platform

The Cerillo Microbiome Discovery Platform offers a comprehensive suite of tools to tackle the challenges of microbiome research head-on. This interconnected platform introduces unprecedented efficiencies, elevating data standardization, reproducibility, and analysis of research findings. Cerillo’s innovative platform includes:

Co-Culture Duet System®: Cerillo’s off-the-shelf microbial interaction platform features duets with porous barriers, allowing researchers to physically isolate populations while maintaining fluidic contact. This enables the observation, study, and growth measurement of individual microbial populations alongside others.

Miniaturized Microplate Readers: Cerillo’s compact microplate readers, like the next-generation Alto™, are ten times smaller than standard ones, perfect for monitoring measurements in tight spaces and anaerobic chambers. Alto is also Ideal for ELISA and high-throughput microbial growth curve applications.

Canopy Wireless Accessory Package: Cerillo’s revolutionary SaaS package offers wireless capabilities and robust software analytics so that researchers can experience real-time data visualization, monitoring, and wireless control of their microplate readers and scale their experiments by connecting multiple readers simultaneously.

 

Learn more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business